# cellvie

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellvie

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.cellvie.bio
- Total disclosed funding: $11M
- Latest round: Series A (Feb 6, 2023)
- Investors on record: 2

## About

Based in the US, cellvie Inc. operates as a biotechnology company specializing in therapeutic solutions that enhance cellular energy metabolism through innovative mitochondrial therapies.Founded in 2018 and headquartered in Houston, US, cellvie Inc. focuses on developing advanced mitochondrial therapies. The company has undergone no notable pivots in its business strategy. The founder and CEO, Alexander Schueller, has a background in biotechnology and was involved in previous ventures. The firm has achieved a total of three deals, with its most recent funding round taking place on February 6, 2023. In this round, cellvie secured USD 5.5 mn in Series A funding led by Taiho Ventures, with participation from KIZOO Technology Ventures and other investors. Overall, cellvie has raised a total of USD 5.5 mn.cellvie Inc. specializes in Therapeutic Mitochondria Transplantation, a treatment aimed at addressing cellular energy metabolism deficiencies. The company focuses on innovative therapies derived from mitochondria, targeting ischemia-reperfusion injury—a critical condition prevalent in heart attacks, strokes, and kidney transplants. Their products are primarily aimed at healthcare providers and institutions in North America and Europe, addressing the demand for advanced options in transplant medicine and regenerative therapies.cellvie's revenue model is centered around B2B partnerships with healthcare institutions, aiming to commercialize its Therapeutic Mitochondria Transplantation technology. The company plans to generate income through negotiated contracts based on treatment volumes, particularly focusing on kidney transplantation applications. This model is anticipated to be crucial, especially concerning delayed graft function, which affects a notable percentage of kidney transplant recipients. The development of a proprietary method for mitochondria transplantation positions cellvie strategically within the biopharmaceutical landscape.Following its Series A funding round in February 2023, where cellvie raised USD 5.5 mn, the company plans to utilize the funds to support the development of its technology platform, accelerate team expansion, and enhance mitochondria manufacturing capabilities. As part of its growth strategy, cellvie aims to launch new therapeutic products targeting cellular energy deficiencies and plans to expand its market reach in both North America and Europe.

## Funding rounds

- Series A, Feb 6, 2023, $5.5M — KIZOO Technology Ventures, Taiho Ventures
- Seed, Jan 25, 2021, $5M — KIZOO Technology Ventures
- Seed, Jan 1, 2020 — KIZOO Technology Ventures

## Investors

- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed, Series A
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A